Analysts Anticipate MacroGenics Inc (NASDAQ:MGNX) to Announce -$0.96 Earnings Per Share

Wall Street brokerages expect MacroGenics Inc (NASDAQ:MGNX) to post ($0.96) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for MacroGenics’ earnings, with estimates ranging from ($1.33) to ($0.38). MacroGenics reported earnings per share of ($1.03) in the same quarter last year, which suggests a positive year over year growth rate of 6.8%. The business is expected to report its next earnings report on Tuesday, August 6th.

On average, analysts expect that MacroGenics will report full year earnings of ($3.75) per share for the current fiscal year, with EPS estimates ranging from ($5.01) to ($2.18). For the next year, analysts expect that the firm will post earnings of ($4.35) per share, with EPS estimates ranging from ($5.47) to ($3.15). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow MacroGenics.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.04). The business had revenue of $9.66 million for the quarter, compared to the consensus estimate of $11.46 million. MacroGenics had a negative net margin of 256.47% and a negative return on equity of 57.65%.

Several equities analysts recently weighed in on MGNX shares. Wedbush set a $39.00 price objective on shares of Allena Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, June 5th. HC Wainwright reiterated a “neutral” rating on shares of Syros Pharmaceuticals in a report on Thursday, May 2nd. ValuEngine downgraded Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, July 8th. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Finally, Guggenheim downgraded Anadarko Petroleum from a “buy” rating to a “hold” rating and set a $69.00 price target on the stock. in a report on Friday, April 12th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $31.62.

MGNX traded down $0.04 during midday trading on Wednesday, hitting $15.17. 418,786 shares of the company’s stock traded hands, compared to its average volume of 1,091,038. The stock has a market capitalization of $776.98 million, a P/E ratio of -3.62 and a beta of 2.37. The company’s fifty day moving average price is $16.33. The company has a current ratio of 6.47, a quick ratio of 6.47 and a debt-to-equity ratio of 0.08. MacroGenics has a one year low of $9.87 and a one year high of $32.32.

In other MacroGenics news, SVP Eric Blasius Risser sold 3,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $18.38, for a total transaction of $55,140.00. Following the transaction, the senior vice president now owns 33,806 shares in the company, valued at $621,354.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 7.88% of the company’s stock.

Several institutional investors have recently made changes to their positions in MGNX. Rhumbline Advisers grew its stake in shares of MacroGenics by 48.8% in the fourth quarter. Rhumbline Advisers now owns 51,665 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 16,950 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of MacroGenics in the fourth quarter worth $965,000. Acadian Asset Management LLC acquired a new stake in shares of MacroGenics in the fourth quarter worth $65,000. BlackRock Inc. grew its stake in shares of MacroGenics by 5.5% in the fourth quarter. BlackRock Inc. now owns 3,401,391 shares of the biopharmaceutical company’s stock worth $43,198,000 after acquiring an additional 176,135 shares during the last quarter. Finally, Citigroup Inc. grew its stake in shares of MacroGenics by 32.4% in the fourth quarter. Citigroup Inc. now owns 52,484 shares of the biopharmaceutical company’s stock worth $667,000 after acquiring an additional 12,844 shares during the last quarter. Institutional investors and hedge funds own 90.52% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Further Reading: How Investors Use a Balance Sheet

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.